As we chronicle the past year, we’re excited to report on our successes, milestones and innovative moments that really mattered. The year 2014 was packed with positive change and evolution—we welcomed new talent, published exciting studies, secured patents, received grants and awards, launched new collaborations and, most notably, integrated with Scott & White for a bigger, better Baylor research team.
With an esteemed team of more than 300 nationally and internationally recognized researchers, the Baylor Scott & White Research Institute (BSWRI) is committed to finding and applying medical and health care delivery innovations within lab and clinical settings. Led by Dr. Michael A. E. Ramsay—a practicing board-certified anesthesiologist and a champion for collaboration and strategic alliances—the team furthers BSWRI’s mission to improve the medical care and well-being of our community through innovative research.
Our reputation for medical innovation and groundbreaking discoveries enhances Baylor Scott & White Health’s ability to attract the most skilled professionals on both the research and the clinical sides.
Director, Federal Home Loan Bank of Dallas (Chairman Elect)
State President, Texas Executive Vice President, Commercial Banking, Capital One Bank
Chairman Emeritus, TXU Corp., President, EN Consulting
Chief Operations Officer
President of the Baylor Research Institute
Chief Operating Officer and Senior Vice President of Research
Chief Financial Officer and Vice President
Vice President and Chief Regulatory Officer
Investigator, Director, Center for Biotechnology, Co-Director of Baylor Institute for Immunology Research
Investigator, Director, Center for Gastrointestinal Research, Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute, Baylor University Medical Center
Director of the Institute of Metabolic Disease at Baylor Research Institute
In the Baylor Scott & White Research Institute Innovation Office, our goal is to help transform BSWH research outcomes into products that will ultimately help patients. In doing so, we evaluate patent, market and license technology developed by BSWH faculty in alignment with our ultimate mission: to enable BSWH investigators to protect and commercialize their innovations, and ultimately to improve the lives of patients by ensuring that Baylor discoveries, treatments and technologies realize their full potential.
Our expansive geographic reach allows Baylor Scott & White Research Institute to offer more patients the opportunity to participate in innovative research right in their neighborhoods. Currently, more than 900 active research studies are underway for a variety of disease states, including immunology, infectious disease, oncology, autoimmune disease and rheumatology, as well as genomics, dermatology, transplantation, metabolic disease and cardiovascular disease.
Additionally, studies related to health care quality highlight innovations associated specifically with the delivery of care. This allows us to serve more than 800,000 people at medical centers in Dallas, Fort Worth, Garland, Grapevine, Irving, Plano, Waxahachie, Denton, Carrollton, Waco, Round Rock, Cedar Park, Brenham, College Station, Llano, Marble Falls, Taylor and Temple.
Within Texas alone, statewide collaborations and joint research efforts are bringing more innovations to Texans than ever. Notably, the merger of Baylor Health Care System with Scott & White Healthcare connected the talents and resources of two major health care systems in North and Central Texas, resulting in a wider geographic reach and broader capabilities. In addition, the Collaborative Faculty Research Investment Program (CFRIP) is a joint initiative from Baylor University, Baylor Scott & White Health and the Baylor College of Medicine that funds selected projects across the state. Additionally, grants from the Cancer Prevention & Research Institute of Texas (CPRIT) have supported Baylor’s oncology research significantly.
In May 2015, Baylor Research Institute and Arizona’s Translational Genomics Research Institute (TGen) launched a unique collaboration related to oncological precision medicine. The significant agreement pairs BRI’s strengths in metabolomics and immune-based approaches with TGen’s forte in genomics and proteomics. As a result, the joint effort, which focuses on early detection and cancer treatment, will give patients greater access to liquid biopsies, gene sequencing, personalized vaccines and expanded clinical trials.
International collaborations extend our reach beyond Texas, allowing BRI researchers to interact with, teach and learn from investigators around the world. This global component provides a unique and exclusive opportunity for local patients to access important clinical trials taking place beyond Texas’ borders.